PRKDC and breast cancer: Our results showed that DNA‐PK tended to be co‐expressed with various functional markers of MDSCs (iNOS, Arg1, and IDO), and that the overall survival time of breast cancer patients with mutations of DNA‐PK and various functional markers of MDSCs (iNOS, Arg1, and IDO) was significantly reduced.